ImmunoPrecise Antibodies Ltd. - Asset Resilience Ratio
ImmunoPrecise Antibodies Ltd. (HYFT) has an Asset Resilience Ratio of 67.58% as of July 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of ImmunoPrecise Antibodies Ltd. to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1997–2020)
This chart shows how ImmunoPrecise Antibodies Ltd.'s Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see HYFT total assets.
Liquid Assets Composition Over Time
This chart breaks down ImmunoPrecise Antibodies Ltd.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore HYFT long-term investments to assets to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $27.54 Million | 67.58% |
| Total Liquid Assets | $27.54 Million | 67.58% |
Asset Resilience Insights
- Very High Liquidity: ImmunoPrecise Antibodies Ltd. maintains exceptional liquid asset reserves at 67.58% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
ImmunoPrecise Antibodies Ltd. Industry Peers by Asset Resilience Ratio
Compare ImmunoPrecise Antibodies Ltd.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for ImmunoPrecise Antibodies Ltd. (1997–2020)
The table below shows the annual Asset Resilience Ratio data for ImmunoPrecise Antibodies Ltd..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2020-04-30 | 0.00% | $104.00 | $27.26 Million | -15.51pp |
| 2016-04-30 | 15.51% | $214.14K | $1.38 Million | +15.22pp |
| 2010-04-30 | 0.30% | $16.20K | $5.47 Million | -0.17pp |
| 2009-04-30 | 0.47% | $32.50K | $6.93 Million | -4.44pp |
| 2008-04-30 | 4.91% | $253.25K | $5.16 Million | +3.85pp |
| 2007-04-30 | 1.06% | $58.75K | $5.56 Million | +0.83pp |
| 2006-04-30 | 0.22% | $9.00K | $4.05 Million | -0.59pp |
| 2001-04-30 | 0.81% | $9.40K | $1.16 Million | +0.24pp |
| 1999-04-30 | 0.57% | $9.40K | $1.66 Million | -6.17pp |
| 1998-04-30 | 6.73% | $197.32K | $2.93 Million | -50.56pp |
| 1997-04-30 | 57.30% | $2.22 Million | $3.88 Million | -- |
About ImmunoPrecise Antibodies Ltd.
MindWalk Holdings Corp. operates as a bio-native AI company. It focuses on the integration of artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics. The company, through its LensAI platform and HYFT technology, it partners with pharmaceutical and biotechnology companies to drive de-risk drug development and unlock ther… Read more